Industry Leaders in China Endometriosis Market | Key Players & Insights 2026

Industry Leaders in China Endometriosis Market

China endometriosis market is characterized by a significant presence of global pharmaceutical players and a rapidly increasing domestic sector centered on localized manufacturing and specialist women's health units. The industry is highly concentrated around established players like Bayer and AbbVie, which lead in hormonal and GnRH antagonist therapies, alongside domestic innovators such as Asieris Pharmaceuticals and Jiangsu Hengrui.

China Endometriosis Market Overview

According to 6Wresearch, the China endometriosis market is projected for significant growth, driven by an aging demographic within the reproductive-age population and a rising clinical focus on fertility preservation. Under the National medicinal Products Administration (NMPA) framework, the market is shifting away from traditional surgical intervention towards long-term medicinal care using oral GnRH antagonists. This transition is being driven by advancements in non-invasive diagnostic imaging and the inclusion of novel hormonal medicines on the National Reimbursement Drug List (NRDL) to improve patient affordability.

Competitive Landscape

The competitive landscape of the China endometriosis market is defined by the presence of global corporations, state-aligned distribution partners, and agile biotech entrepreneurs. These organizations make significant investments in research and development for next-generation oral modulators and non-hormonal biological treatments to meet the increasing industrial demand for treating endometriosis-related infertility and chronic pelvic pain.

Below is a list of leading players operating in the China Endometriosis Market:

1. Bayer AG

A dominant force in the Chinese market, Bayer provides the industry-leading progestin therapy Visanne (dienogest) and leverages a robust women’s health portfolio.

2. AbbVie Inc.

Renowned for its leadership in GnRH antagonists, AbbVie markets Orilissa (elagolix) and focuses on setting high clinical standards for non-surgical pain management.

3. Asieris Pharmaceuticals

A leading domestic innovator that established a dedicated women's health unit in 2024 to advance non-surgical treatments and personalized gynecological care.

4. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

One of China's largest pharmaceutical firms, focusing on R&D for small-molecule anti-inflammatory drugs and hormonal modulators used in long-term endometriosis maintenance.

5. Pfizer Inc.

Maintains a significant market share through established hormonal products and its strategic collaboration on the GnRH antagonist Myfembree/Ryeqo.

6. Takeda Pharmaceutical Company Limited

A key provider of GnRH agonists like Leuplin (leuprorelin), which remains a staple treatment in major Chinese hospital networks.

7. Organon China

Focused exclusively on women's health, Organon manages a wide array of progestin-based treatments and contraceptives essential for symptom suppression.

8. Sinopharm Group Co. Ltd.

As the largest pharmaceutical distributor in China, Sinopharm ensures the national supply and accessibility of both domestic and imported gynecological medications.

9. Zhejiang Xianju Pharmaceutical Co., Ltd.

A specialized domestic manufacturer of steroid hormones, acting as a critical supplier of active pharmaceutical ingredients (APIs) for endometriosis therapies.

10. Sumitomo Pharma Co., Ltd.

Engaged in the commercialization of advanced hormonal modulators and oral GnRH antagonists in the Asia-Pacific region.

11. TiumBio

An emerging biotech actively developing Merigolix, an oral GnRH antagonist that has shown positive clinical results in reducing endometriosis-related pain.

12. Gedeon Richter Plc.

A global leader in women’s health with a specialized focus on uterine fibroids and endometriosis treatments available across the Chinese market.

13. Zydus Healthcare Limited

A major manufacturer of high-quality generic hormonal therapies, contributing to the affordability of long-term endometriosis management.

14. Ferring Pharmaceuticals

Specializes in reproductive medicine, providing hormonal therapies that assist endometriosis patients with associated fertility challenges.

Industry Leaders in China Endometriosis Market